| http://dbpedia.org/ontology/abstract
|
Genmab är ett danskt läkemedelsbolag som utvecklar antikroppsbaserade läkemedel. Företaget bildades i februari 1999 i Köpenhamn af Florian Schönharting. År 2000 noterades bolaget på Köpenhamnsbörsen och Frankfurtbörsen.
, Genmab A/S é uma empresa dinamarquesa de b … Genmab A/S é uma empresa dinamarquesa de biotecnologia. Foi fundada em Fevereiro de 1999 pelo BankInvest Biomedical, liderado por Florian Schönharting. A empresa tem a sua sede em Copenhaga. A nível internacional, opera através das suas suas subsidiárias Genmab BV em Utrecht, Países Baixos e Genmab, Inc em Princeton, New Jersey, Estados Unidos da América. A empresa encontra-se cotada na bolsa de Copenhaga, integrando o índice OMX Copenhagen 20.ga, integrando o índice OMX Copenhagen 20.
, Genmab A/S — датская фармацевтическая компания. Акции компании обращаются на бирже .
, Genmab A/S adalah sebuah Denmark, yang dib … Genmab A/S adalah sebuah Denmark, yang dibentuk pada Februari 1999 oleh Florian Schönharting, pada masa ia menjadi direktur manajer yayasan perusahaan BankInvest Biomedical. Perusahaan tersebut berbasis di Copenhagen, Denmark - secara internasional, perusahaan tersebut beroperasi melalui cabang-cabang Genmab B.V. di Utrecht, Belanda, Genmab U.S., Inc. di Princeton, Amerika Serikat, dan Genmab K.K. di Tokyo, Jepang. Perusahaan tersebut adalah perusahaan terdaftar ganda dengan saham diperdagangkan pada di Denmark, dan pada NASDAQ Global Select Market di Amerika Serikat.Q Global Select Market di Amerika Serikat.
, ジェンマブ（デンマーク語: Genmab A/S）は、デンマーク・コペンハーゲンに本社を置くバイオテクノロジー企業。慢性リンパ性白血病治療薬のオファツムマブ（Arzerra）や多発性骨髄腫治療薬のダラツムマブ（Darzalex）の特許を保有する。ナスダック・コペンハーゲン上場企業（Nasdaq Nordic GEN）。
, Genmab A/S is a Danish biotechnology compa … Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. The company has 6 approved antibodies used in 6 marketed products, covering cancer indications and autoimmune diseases: Proprietary, marketed with Seagen:
* Tivdak (tisotumab vedotin-tftv) for the treatment of previously treated recurrent or metastatic cervical cancer Marketed by partners:
* Darzalex (IV) (daratumumab) / Darzalex Faspro (SC) (daratumumab and hyaluronidase-fihj) for the treatment of all stages of multiple myeloma as combination therapy or monotherapy, and for the treatment of newly diagnosed amyloid light-chain (AL) amyloidosis (Janssen)
* Rybrevant (amivantamab-vmjw) for the treatment of non-small-cell lung cancer (EGFR exon 20 insertion mutations) (Janssen)
* Tecvayli (teclistamab) for the treatment of relapsed or refractory MM (Janssen)
* Kesimpta (ofatumumab) for the treatment of relapsing remitting multiple sclerosis (Novartis)
* Tepezza (teprotumumab-trbw) for the treatment of thyroid eye disease (Horizon) Furthermore both Genmab and its partners have a whole range of antibody programs, building on Genmab technologies, in clinical and pre-clinical development. Genmab have several late stage clinical programs for tisotumab vedotin (cervical cancer, ovarian cancer and solid tumors) and epcoritamab (diffuse large B-cell lymphoma and B-cell non-Hodgkin lymphoma). The partners have, among others, clinical programs for daratumumab (non-MM blood cancers), amivantamab (gastric cancer and esophageal cancer), and teprotumumab (diffuse cutaneous systemic sclerosis).ab (diffuse cutaneous systemic sclerosis).
, Genmab ist ein dänisches Unternehmen auf d … Genmab ist ein dänisches Unternehmen auf dem Gebiet der roten Biotechnologie. Genmab entwickelt und produziert monoklonale Antikörper für die onkologische Therapie. Das Unternehmen wurde 1999 in Kopenhagen gegründet und ging im Jahr 2000 an die Börse in Kopenhagen und Frankfurt. Das IPO erbrachte 1,56 Milliarden Dänische Kronen (rund 209 Millionen Euro). Zwei Jahre später, 2002, wurde das Unternehmen in Frankfurt wieder delisted. Es bestehen mehrere Entwicklungs- und Kommerzialisierungsverträge mit Pharmakonzernen wie Hoffmann-La Roche, GlaxoSmithKline und Novartis. Ein von Genmab produzierter Antikörper ist Ofatumumab, dessen Vermarktungsrechte in 2015 komplett an Novartis abgegeben wurden.015 komplett an Novartis abgegeben wurden.
|
| http://dbpedia.org/ontology/foundedBy
|
http://dbpedia.org/resource/Florian_Sch%C3%B6nharting +
|
| http://dbpedia.org/ontology/foundingYear
|
1999
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/ontology/keyPerson
|
http://dbpedia.org/resource/President_%28corporate_title%29 +
, http://dbpedia.org/resource/CEO +
, http://dbpedia.org/resource/Chairperson +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/Denmark +
, http://dbpedia.org/resource/Copenhagen +
|
| http://dbpedia.org/ontology/netIncome
|
3.008E9
|
| http://dbpedia.org/ontology/numberOfEmployees
|
1212
|
| http://dbpedia.org/ontology/numberOfLocations
|
4
|
| http://dbpedia.org/ontology/operatingIncome
|
3.018E9
|
| http://dbpedia.org/ontology/product
|
http://dbpedia.org/resource/Amivantamab +
, http://dbpedia.org/resource/Tisotumab_vedotin +
, http://dbpedia.org/resource/Ofatumumab +
, http://dbpedia.org/resource/Teprotumumab +
, http://dbpedia.org/resource/Daratumumab +
, http://dbpedia.org/resource/Teclistamab +
, http://dbpedia.org/resource/Daratumumab/hyaluronidase +
|
| http://dbpedia.org/ontology/revenue
|
8.482E9
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Genmab.svg?width=300 +
|
| http://dbpedia.org/ontology/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/ontology/wikiPageID
|
14776158
|
| http://dbpedia.org/ontology/wikiPageLength
|
26509
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1118676701
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Seagen +
, http://dbpedia.org/resource/Blood_cancer +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_Denmark +
, http://dbpedia.org/resource/Category:Life_science_companies_based_in_Copenhagen +
, http://dbpedia.org/resource/BioNTech +
, http://dbpedia.org/resource/CD38 +
, http://dbpedia.org/resource/Lundbeck +
, http://dbpedia.org/resource/Donald_L._Drakeman +
, http://dbpedia.org/resource/Copenhagen_Stock_Exchange +
, http://dbpedia.org/resource/Daratumumab +
, http://dbpedia.org/resource/Japan +
, http://dbpedia.org/resource/Brooklyn_Park%2C_Minnesota +
, http://dbpedia.org/resource/Public_company +
, http://dbpedia.org/resource/Medarex +
, http://dbpedia.org/resource/Coeliac_disease +
, http://dbpedia.org/resource/Haemophilia_A +
, http://dbpedia.org/resource/CEO +
, http://dbpedia.org/resource/Sickle_cell_disease +
, http://dbpedia.org/resource/Biotechnology_company +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Multiple_myeloma +
, http://dbpedia.org/resource/Daratumumab/hyaluronidase +
, http://dbpedia.org/resource/Diffuse_large_B-cell_lymphoma +
, http://dbpedia.org/resource/Chief_scientific_officer +
, http://dbpedia.org/resource/Utrecht_Science_Park +
, http://dbpedia.org/resource/Chairperson +
, http://dbpedia.org/resource/Category:Biotechnology_companies_established_in_1999 +
, http://dbpedia.org/resource/C-Met +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_1999 +
, http://dbpedia.org/resource/Factor_VIII_%28medication%29 +
, http://dbpedia.org/resource/B-cell_chronic_lymphocytic_leukemia +
, http://dbpedia.org/resource/Janssen_Pharmaceuticals +
, http://dbpedia.org/resource/Tissue_factor +
, http://dbpedia.org/resource/Biotechnology_Industry_Organization +
, http://dbpedia.org/resource/IgG4 +
, http://dbpedia.org/resource/Factor_X +
, http://dbpedia.org/resource/Alpha-synuclein +
, http://dbpedia.org/resource/Graves%27_ophthalmopathy +
, http://dbpedia.org/resource/AbbVie +
, http://dbpedia.org/resource/Rybrevant +
, http://dbpedia.org/resource/IGF-1R +
, http://dbpedia.org/resource/Category:Danish_companies_established_in_1999 +
, http://dbpedia.org/resource/Category:Dual-listed_companies +
, http://dbpedia.org/resource/4-1bb +
, http://dbpedia.org/resource/Florian_Sch%C3%B6nharting +
, http://dbpedia.org/resource/IL2RA +
, http://dbpedia.org/resource/Selectin_P +
, http://dbpedia.org/resource/Follicular_non-Hodgkin%27s_lymphoma +
, http://dbpedia.org/resource/Long_Island_Life_Sciences_Initiative +
, http://dbpedia.org/resource/Mim8 +
, http://dbpedia.org/resource/Hodgkin_lymphoma +
, http://dbpedia.org/resource/Epcoritamab +
, http://dbpedia.org/resource/James_D._Watson_Helix_Award +
, http://dbpedia.org/resource/Talquetamab +
, http://dbpedia.org/resource/Netherlands +
, http://dbpedia.org/resource/Esophageal_cancer +
, http://dbpedia.org/resource/Multiple_system_atrophy +
, http://dbpedia.org/resource/Stomach_cancer +
, http://dbpedia.org/resource/Write-off +
, http://dbpedia.org/resource/Copenhagen +
, http://dbpedia.org/resource/Vaso-occlusive_crisis +
, http://dbpedia.org/resource/Chronic_lymphocytic_leukemia +
, http://dbpedia.org/resource/Combination_therapy +
, http://dbpedia.org/resource/Aktieselskab +
, http://dbpedia.org/resource/CD37 +
, http://dbpedia.org/resource/Category:Companies_listed_on_Nasdaq_Copenhagen +
, http://dbpedia.org/resource/Princeton%2C_New_Jersey +
, http://dbpedia.org/resource/Novartis +
, http://dbpedia.org/resource/Factor_IX +
, http://dbpedia.org/resource/Ofatumumab +
, http://dbpedia.org/resource/Teprotumumab +
, http://dbpedia.org/resource/Non-small-cell_lung_cancer +
, http://dbpedia.org/resource/Relapsing_remitting_multiple_sclerosis +
, http://dbpedia.org/resource/Category:Companies_based_in_Copenhagen_Municipality +
, http://dbpedia.org/resource/Inclacumab +
, http://dbpedia.org/resource/United_States +
, http://dbpedia.org/resource/AL_amyloidosis +
, http://dbpedia.org/resource/Tokyo +
, http://dbpedia.org/resource/GPRC5D +
, http://dbpedia.org/resource/Teclistamab +
, http://dbpedia.org/resource/Novo_Nordisk +
, http://dbpedia.org/resource/PDL_BioPharma +
, http://dbpedia.org/resource/CD20 +
, http://dbpedia.org/resource/Utrecht +
, http://dbpedia.org/resource/Cervical_cancer +
, http://dbpedia.org/resource/B-cell_maturation_antigen +
, http://dbpedia.org/resource/NASDAQ +
, http://dbpedia.org/resource/Neoplasm +
, http://dbpedia.org/resource/Danish_krone +
, http://dbpedia.org/resource/Denmark +
, http://dbpedia.org/resource/Category:Danish_brands +
, http://dbpedia.org/resource/Interleukin_15 +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_Denmark +
, http://dbpedia.org/resource/Baxter_International +
, http://dbpedia.org/resource/Intravenous_infusion +
, http://dbpedia.org/resource/Multiple_sclerosis +
, http://dbpedia.org/resource/VTCN1 +
, http://dbpedia.org/resource/CD40 +
, http://dbpedia.org/resource/Non-Hodgkin_lymphoma +
, http://dbpedia.org/resource/Rheumatoid_arthritis +
, http://dbpedia.org/resource/PD-L1 +
, http://dbpedia.org/resource/Subcutaneous_injection +
, http://dbpedia.org/resource/Amivantamab +
, http://dbpedia.org/resource/Bristol-Myers_Squibb +
, http://dbpedia.org/resource/Chief_executive_officer +
, http://dbpedia.org/resource/Systemic_scleroderma +
, http://dbpedia.org/resource/Camidanlumab_tesirine +
, http://dbpedia.org/resource/Horizon_Therapeutics +
, http://dbpedia.org/resource/CD3_%28immunology%29 +
, http://dbpedia.org/resource/Utrecht_%28city%29 +
, http://dbpedia.org/resource/Epidermal_growth_factor_receptor +
, http://dbpedia.org/resource/GlaxoSmithKline +
, http://dbpedia.org/resource/President_%28corporate_title%29 +
, http://dbpedia.org/resource/Interleukin_8 +
, http://dbpedia.org/resource/ADC_Therapeutics +
, http://dbpedia.org/resource/Ovarian_cancer +
, http://dbpedia.org/resource/Hoffmann-La_Roche +
, http://dbpedia.org/resource/Tisotumab_vedotin +
, http://dbpedia.org/resource/Tumors_of_the_hematopoietic_and_lymphoid_tissues +
|
| http://dbpedia.org/property/founder
|
Florian Schönharting and Lisa Drakeman
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/property/keyPeople
|
Jan Van de Winkel
, Deirdre P. Connelly
|
| http://dbpedia.org/property/location
|
http://dbpedia.org/resource/Denmark +
, http://dbpedia.org/resource/Copenhagen +
|
| http://dbpedia.org/property/logo
|
Genmab.svg
|
| http://dbpedia.org/property/logoSize
|
250
|
| http://dbpedia.org/property/name
|
Genmab A/S
|
| http://dbpedia.org/property/netIncome
|
3.008E9
|
| http://dbpedia.org/property/numEmployees
|
1212
|
| http://dbpedia.org/property/numLocations
|
4
|
| http://dbpedia.org/property/operatingIncome
|
3.018E9
|
| http://dbpedia.org/property/products
|
http://dbpedia.org/resource/Daratumumab/hyaluronidase +
, http://dbpedia.org/resource/Daratumumab +
, Tivdak
, RYBREVANT
, TEPEZZA
, TECVAYLI
, Kesimpta
|
| http://dbpedia.org/property/revenue
|
8.482E9
|
| http://dbpedia.org/property/type
|
http://dbpedia.org/resource/Aktieselskab +
, http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:OMX +
, http://dbpedia.org/resource/Template:Failed_verification +
, http://dbpedia.org/resource/Template:As_of +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Authority_control +
, http://dbpedia.org/resource/Template:OMX_Copenhagen_20_companies +
, http://dbpedia.org/resource/Template:Start_date_and_age +
|
| http://dbpedia.org/property/wordnet type
|
http://www.w3.org/2006/03/wn/wn20/instances/synset-company-noun-1 +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Danish_companies_established_in_1999 +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_Denmark +
, http://dbpedia.org/resource/Category:Life_science_companies_based_in_Copenhagen +
, http://dbpedia.org/resource/Category:Companies_listed_on_Nasdaq_Copenhagen +
, http://dbpedia.org/resource/Category:Danish_brands +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_1999 +
, http://dbpedia.org/resource/Category:Biotechnology_companies_established_in_1999 +
, http://dbpedia.org/resource/Category:Dual-listed_companies +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_Denmark +
, http://dbpedia.org/resource/Category:Companies_based_in_Copenhagen_Municipality +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Company +
|
| http://www.w3.org/2004/02/skos/core#closeMatch
|
http://www.grid.ac/institutes/grid.466767.2 +
, http://www.grid.ac/institutes/grid.476284.b +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Genmab?oldid=1118676701&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Genmab.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Genmab +
|
| http://xmlns.com/foaf/0.1/name
|
Genmab A/S
|
| owl:sameAs |
http://fa.dbpedia.org/resource/%D8%AC%D9%86%D9%85%D8%A8 +
, http://da.dbpedia.org/resource/Genmab +
, http://pt.dbpedia.org/resource/Genmab +
, http://id.dbpedia.org/resource/Genmab +
, http://de.dbpedia.org/resource/Genmab +
, http://dbpedia.org/resource/Genmab +
, http://ms.dbpedia.org/resource/Genmab +
, http://fi.dbpedia.org/resource/Genmab +
, http://rdf.freebase.com/ns/m.03gxm_3 +
, http://www.wikidata.org/entity/Q2076526 +
, https://global.dbpedia.org/id/yiFX +
, http://yago-knowledge.org/resource/Genmab +
, http://sv.dbpedia.org/resource/Genmab +
, http://ja.dbpedia.org/resource/%E3%82%B8%E3%82%A7%E3%83%B3%E3%83%9E%E3%83%96 +
, http://ru.dbpedia.org/resource/Genmab +
|
| rdf:type |
http://dbpedia.org/ontology/Company +
, http://dbpedia.org/class/yago/DrugCompany108002578 +
, http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/class/yago/WikicatLifeScienceCompaniesBasedInCopenhagen +
, http://dbpedia.org/class/yago/WikicatBiotechnologyCompaniesOfDenmark +
, http://dbpedia.org/class/yago/WikicatPharmaceuticalCompaniesOfDenmark +
, http://dbpedia.org/class/yago/Company108058098 +
, http://schema.org/Organization +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://dbpedia.org/ontology/Organisation +
, http://dbpedia.org/class/yago/WikicatPharmaceuticalCompaniesEstablishedIn1999 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Institution108053576 +
, http://dbpedia.org/class/yago/SocialGroup107950920 +
, http://www.wikidata.org/entity/Q4830453 +
, http://www.wikidata.org/entity/Q43229 +
, http://dbpedia.org/ontology/Agent +
, http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/YagoLegalActor +
, http://www.wikidata.org/entity/Q24229398 +
, http://dbpedia.org/class/yago/Organization108008335 +
, http://dbpedia.org/class/yago/Group100031264 +
|
| rdfs:comment |
Genmab A/S is a Danish biotechnology compa … Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. Proprietary, marketed with Seagen: Marketed by partners:arketed with Seagen: Marketed by partners:
, ジェンマブ（デンマーク語: Genmab A/S）は、デンマーク・コペンハーゲンに本社を置くバイオテクノロジー企業。慢性リンパ性白血病治療薬のオファツムマブ（Arzerra）や多発性骨髄腫治療薬のダラツムマブ（Darzalex）の特許を保有する。ナスダック・コペンハーゲン上場企業（Nasdaq Nordic GEN）。
, Genmab A/S adalah sebuah Denmark, yang dib … Genmab A/S adalah sebuah Denmark, yang dibentuk pada Februari 1999 oleh Florian Schönharting, pada masa ia menjadi direktur manajer yayasan perusahaan BankInvest Biomedical. Perusahaan tersebut berbasis di Copenhagen, Denmark - secara internasional, perusahaan tersebut beroperasi melalui cabang-cabang Genmab B.V. di Utrecht, Belanda, Genmab U.S., Inc. di Princeton, Amerika Serikat, dan Genmab K.K. di Tokyo, Jepang. Perusahaan tersebut adalah perusahaan terdaftar ganda dengan saham diperdagangkan pada di Denmark, dan pada NASDAQ Global Select Market di Amerika Serikat.Q Global Select Market di Amerika Serikat.
, Genmab ist ein dänisches Unternehmen auf d … Genmab ist ein dänisches Unternehmen auf dem Gebiet der roten Biotechnologie. Genmab entwickelt und produziert monoklonale Antikörper für die onkologische Therapie. Das Unternehmen wurde 1999 in Kopenhagen gegründet und ging im Jahr 2000 an die Börse in Kopenhagen und Frankfurt. Das IPO erbrachte 1,56 Milliarden Dänische Kronen (rund 209 Millionen Euro). Zwei Jahre später, 2002, wurde das Unternehmen in Frankfurt wieder delisted. Es bestehen mehrere Entwicklungs- und Kommerzialisierungsverträge mit Pharmakonzernen wie Hoffmann-La Roche, GlaxoSmithKline und Novartis.nn-La Roche, GlaxoSmithKline und Novartis.
, Genmab är ett danskt läkemedelsbolag som utvecklar antikroppsbaserade läkemedel. Företaget bildades i februari 1999 i Köpenhamn af Florian Schönharting. År 2000 noterades bolaget på Köpenhamnsbörsen och Frankfurtbörsen.
, Genmab A/S é uma empresa dinamarquesa de b … Genmab A/S é uma empresa dinamarquesa de biotecnologia. Foi fundada em Fevereiro de 1999 pelo BankInvest Biomedical, liderado por Florian Schönharting. A empresa tem a sua sede em Copenhaga. A nível internacional, opera através das suas suas subsidiárias Genmab BV em Utrecht, Países Baixos e Genmab, Inc em Princeton, New Jersey, Estados Unidos da América. A empresa encontra-se cotada na bolsa de Copenhaga, integrando o índice OMX Copenhagen 20.ga, integrando o índice OMX Copenhagen 20.
, Genmab A/S — датская фармацевтическая компания. Акции компании обращаются на бирже .
|
| rdfs:label |
ジェンマブ
, Genmab
|
